Cargando…

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies

Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug testing on primary CLL cells and identified synerg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melvold, Katrine, Giliberto, Mariaserena, Karlsen, Linda, Ayuda‐Durán, Pilar, Hanes, Robert, Holien, Toril, Enserink, Jorrit, Brown, Jennifer R., Tjønnfjord, Geir E., Taskén, Kjetil, Skånland, Sigrid S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895453/ https://www.ncbi.nlm.nih.gov/pubmed/34861096 http://dx.doi.org/10.1002/1878-0261.13153

Ejemplares similares

Standardized assays to monitor drug sensitivity in hematologic cancers
por: Ayuda-Durán, Pilar, et al.
Publicado: (2023)

Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
por: Giliberto, Mariaserena, et al.
Publicado: (2022)

A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
por: Hermansen, Johanne U., et al.
Publicado: (2023)

Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
por: Giliberto, Mariaserena, et al.
Publicado: (2022)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

P613: ANALYSIS OF EX-VIVO RESPONSE TO SINGLE DRUGS AND DRUG COMBINATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENT SAMPLES
por: Miranda Santana, Leonardo, et al.
Publicado: (2023)

Cryopreservation of primary B cells minimally influences their signaling responses
por: Hermansen, Johanne U., et al.
Publicado: (2018)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
por: Mena, Salvador, et al.
Publicado: (2012)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines
por: Abdul Rahman, Siti Fairus, et al.
Publicado: (2020)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

Computational design of an apoptogenic protein that binds BCL-xL and MCL-1 simultaneously and potently
por: Kim, Seonghoon, et al.
Publicado: (2022)

Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1
por: Ow, Thomas J., et al.
Publicado: (2019)

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
por: Schneller, Anja, et al.
Publicado: (2021)

ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
por: Alcon, Clara, et al.
Publicado: (2021)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Yosef, Reut, et al.
Publicado: (2016)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL
por: Vikström, Ingela B, et al.
Publicado: (2016)

Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation
por: Opydo, Małgorzata, et al.
Publicado: (2023)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia
por: Myhrvold, Ida K., et al.
Publicado: (2018)

The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition
por: Peddaboina, Chander, et al.
Publicado: (2012)

Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells
por: Abdul Rahman, Siti Fairus, et al.
Publicado: (2022)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263
por: Huang, Tianlu, et al.
Publicado: (2019)

Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

Bcl-XL and Bcl-2 repress a common pathway of cell death
Publicado: (1995)

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

Nutritional Regulators of Bcl-xL in the Brain
por: Park, Han-A, et al.
Publicado: (2018)

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
por: Shebl, Bassem, et al.
Publicado: (2022)

Determining drug dose in the era of targeted therapies: playing it (un)safe?
por: Skånland, Sigrid S., et al.
Publicado: (2022)

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage
por: Seng, NS, et al.
Publicado: (2016)

Mcl-1 expression and JNK activation induces a threshold for apoptosis in Bcl-xL-overexpressing hematopoietic cells
por: Zhang, Yu, et al.
Publicado: (2016)

Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors
por: Senichkin, Viacheslav V., et al.
Publicado: (2021)

The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance
por: Fitzgerald, Marie-Claire, et al.
Publicado: (2023)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ng0qe0bmj68ldnmputl56kup3b